PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · New England Journal of Medicine · 2018 · 3.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Mitotic progression following DNA damage enables pattern recognition within micronuclei

Shane M. Harding, Joseph L. Benci, Jerome Irianto et al. · Nature · 2017 · 1.5K citations

Medicine, Oncology, Radiation Oncology +17

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

Simon J. Dovedi, Amy L. Adlard, Grazyna Lipowska‐Bhalla et al. · Cancer Research · 2014 · 1.3K citations · Full text

Life Sciences, Immunology, Oncology +17

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

Shiping Jiao, Weiya Xia, Hirohito Yamaguchi et al. · Clinical Cancer Research · 2017 · 975 citations

Medicine, Immunology, Oncology +17